Lapatinib ditosylate hydrate

Modify Date: 2024-01-02 18:53:29

Lapatinib ditosylate hydrate structure	Common Name	Lapatinib ditosylate hydrate
	CAS Number	388082-78-8	Molecular Weight	943.476
	Density	1.403 g/mL (20.84 °C)	Boiling Point	750.7ºC at 760 mmHg
	Molecular Formula	C₈₆H₈₆Cl₂F₂N₈O₂₁S₆	Melting Point	237 - 239 °C
	MSDS	N/A	Flash Point	68 °F

Use of Lapatinib ditosylate hydrate

Lapatinib ditosylate monohydrate (GW572016 ditosylate monohydrate) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1].

Name	Lapatinib ditosylate
Synonym	More Synonyms

Description	Lapatinib ditosylate monohydrate (GW572016 ditosylate monohydrate) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> JAK/STAT Signaling >> EGFR Signaling Pathways >> Protein Tyrosine Kinase/RTK >> EGFR Signaling Pathways >> Autophagy >> Autophagy
Target	EGFR:10.8 nM (IC50) ErbB2:9.2 nM (IC50)
In Vitro	Lapatinib (GW2016; 0.03-10 µM; 6 hours; BT474 and HN5 cells) treatment inhibits receptor autophosphorylation of EGFR and ErbB-2 in a dose-responsive manner. Phosphorylation of serine 473 of AKT was inhibited by GW2016 in a dose-dependent manner[1]. Lapatinib (GW2016; 72 hours; HN5, A-43, BT474, N87, and CaLu-3 cells) treatment has a selective inhibition of the proliferation of human tumor cell lines[1]. Lapatinib (GW2016; 1-10 µM; 72 hours; HN5 cells) treatment results in induces G1 arrest[1]. Western Blot Analysis[1] Cell Line: BT474 and HN5 cells Concentration: 0.03 µM, 0.1 µM, 0.3 µM, 1 µM, 3 µM, or 10 µM Incubation Time: 6 hours Result: Inhibited receptor autophosphorylation of EGFR and ErbB-2 in a dose-responsive manner. Phosphorylation of serine 473 of AKT was also inhibited in a dose-dependent manner. Cell Proliferation Assay[1] Cell Line: HN5, A-43, BT474, N87, and CaLu-3 cells Concentration: Incubation Time: 72 hours Result: Inhibited the growth of tumor cells overexpressing EGFR or ErbB-2. Cell Cycle Analysis[1] Cell Line: HN5 cells Concentration: 1 µM, or 10 µM Incubation Time: 72 hours Result: Resulted in induction of G1 arrest.
In Vivo	Lapatinib (GW2016; 30-100 mg/kg; oral administration; twice daily; for 21 days; CD-1 nude female mice) treatment inhibits tumor xenograft growth of the HN5 cells in a dose-responsive manner at 30 and 100 mg/kg, with complete inhibition of tumor growth at the higher dose[1]. Animal Model: CD-1 nude female mice (4-6 weeks old) with HN5 cells[1] Dosage: 30 mg/kg, 100 mg/kg Administration: Oral administration; twice daily; for 21 days Result: Inhibited tumor xenograft growth of the HN5 cells in a dose-responsive manner.
References	[1]. Rusnak DW, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 2001 Dec;1(2):85-94.

Density	1.403 g/mL (20.84 °C)
Boiling Point	750.7ºC at 760 mmHg
Melting Point	237 - 239 °C
Molecular Formula	C₈₆H₈₆Cl₂F₂N₈O₂₁S₆
Molecular Weight	943.476
Flash Point	68 °F
Exact Mass	942.184143
PSA	249.46000
LogP	12.26450
Index of Refraction	n20/D 1.5520(lit.)

Hazard Codes	Xi,N
Risk Phrases	R43:May cause sensitization by skin contact. R51/53:Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment .
Safety Phrases	S24-S37-S61

Precursor 9
CAS#:104-15-4 p-Toluenesulfon... CAS#:104458-24-4 2-Aminoethylmet... CAS#:231278-84-5 5-[4-[3-chloro-... CAS#:49773-20-8 2-Aminoethyl me...
CAS#:1227853-06-6 N-(3-chloro-4-(... CAS#:231277-92-2 Lapatinib (GW572016) CAS#:231278-20-9 N-(3-Chloro-4-(... CAS#:1885-29-6 aminobenzonitrile
CAS#:132131-24-9 2-Amino-5-iodob...
DownStream 1
CAS#:231277-92-2 Lapatinib (GW572016)

N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]quinazolin-4-amine bis(4-methylbenzenesulfonate) hydrate

N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine 4-methylbenzenesulfonate hydrate (1:2:1)

Lapatinib ditosylate (USAN)

N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamine, 4-methylbenzenesulfonate, hydrate (1:2:1)

T66 BN DNJ EMR CG DO1R CF&& H- BT5OJ E1M2SW1 &&2 p-Tosoh H2O

Lapatinib Ditosilate

4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-, 4-methylbenzenesulfonate, hydrate (1:2:1)

Lapatinib ditosylate monohydrate

Lapatinib Ditosylate